Valuation: Gilead Sciences, Inc.

Market Cap 164B 143B 132B 121B 230B 15,734B 234B 1,574B 618B 7,690B 614B 601B 26,506B P/E 2026 *
-47.4x
P/E 2027 * 16.7x
Enterprise Value 173B 151B 140B 128B 243B 16,644B 247B 1,666B 653B 8,135B 650B 635B 28,040B EV / Sales 2026 *
5.68x
EV / Sales 2027 * 5.05x
Free-Float
99.88%
Yield 2026 *
2.46%
Yield 2027 * 2.55%
1 day+1.28%
1 week-3.03%
Current month+4.24%
1 month+5.95%
3 months-5.77%
6 months+8.61%
Current year+7.30%
1 week 127.94
Extreme 127.935
134.97
1 month 122.43
Extreme 122.43
137.7
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
Jun. 30Sell

Chief Executive Officer

-15,000 0.0012%
Jun. 14Sell

Executive/Senior Manager

-3,000 0.0002%
Jun. 14Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+1.28%-3.03%+20.76%+70.62% 164B
+0.35%-4.87%+49.87%+157.34% 1,031B
-2.69%-6.22%+59.19%+54.51% 595B
+0.44%-3.41%+30.97%+79.48% 431B
+0.98%-1.40%+29.49%+21.76% 326B
-0.34%-3.10%+27.00%+43.60% 277B
+1.63%-11.76%+19.72%+21.72% 263B
+3.39%+2.29%-23.68%-37.83% 224B
+0.86%-2.63%+22.50%+57.55% 193B
+2.35%+3.20%+0.85%-31.66% 141B
Average +0.81%-3.09%+23.67%+43.71% 364.58B
Weighted average by Cap. +0.29%-4.02%+34.24%+72.30%

Financials

2026 *2027 *
Net sales 30.47B 26.64B 24.57B 22.59B 42.8B 2,932B 43.53B 293B 115B 1,433B 114B 112B 4,939B 32.4B 28.33B 26.13B 24.02B 45.51B 3,118B 46.29B 312B 122B 1,524B 122B 119B 5,252B
Net income -3.39B -2.96B -2.73B -2.51B -4.76B -326B -4.85B -32.65B -12.81B -159B -12.73B -12.46B -550B 9.76B 8.53B 7.87B 7.24B 13.71B 939B 13.95B 93.99B 36.88B 459B 36.66B 35.86B 1,582B
Net Debt 9.46B 8.27B 7.63B 7.01B 13.29B 910B 13.52B 91.09B 35.74B 445B 35.53B 34.75B 1,534B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-15 $131.70 +1.28% 4,467,637
26-07-14 $130.04 -1.04% 5,255,960
26-07-13 $131.40 +1.21% 5,131,594
26-07-10 $129.83 -3.72% 5,935,997
26-07-09 $134.84 -0.72% 5,839,339
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
131.70USD
Average target price
158.30USD
Spread / Average Target
+20.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock